Condition: Systemic Lupus Erthematosus (SLE) · Lupus Nephritis (LN) · Extra-renal Lupus (ERL) · Sponsor: Hinge Bio
This Phase 1, open label, dose escalation study evaluates the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of HB2198, a tetravalent bispecific anti CD19/CD20 antibody, in adults with moderately to severely active systemic lupus erythematosus (SLE), including lupus nephritis and extra renal lupus. Approximately 30 participants will receive two intravenous doses of HB2198 and be followed for 12 months to assess safety, B cell depletion, disease activity, immunologic biomarkers, and renal outcomes.
This description comes directly from the study's public registry record.
Joshua Pelham · 1-415-378-4738 · joshua.pelham@hingebio.com
Kristen Quigley · kristen.quigley@hingebio.com
Always discuss trial participation with your own doctor first.
| Investigational site | Brisbane, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07491900